Patient characteristics, treatment, clinical outcome, and tumor characterization
| Patient | Age | Breed | Gender | CAV vacc. | dCelyvir doses | RAVNO | Tumor location | Diagnosis |
| 1 | 8 | French Bulldog | M | 8 | 8 | PD | Temp. | Olig. III |
| 2 | 6 | French Bulldog | M | 3 | 11 | PD | Frontal | Olig. III |
| 3 | 7 | Poodle | M | 1 | 8 | PR | Temp.+Occ. | Olig. III |
| 4 | 9 | English Bulldog | F | 11 | 1 | N/A | Temp.+Th. | N/A |
| 5 | 9 | Boxer | F | 35 | 12 | SD | Frontal | Olig. III |
| 6 | 9 | Boxer | M | 5 | 14 | SD | Frontal | GBM |
| 7 | 10 | French Bulldog | M | 4 | 12 | SD | Frontal+Th. | GBM |
| 8 | 6 | French Bulldog | M | 5 | 5 | N/A | Frontal+parietal + Temp.+Th. | Olig. III |
| 9 | 8 | French Bulldog | F | 10 | 17 | PR | Parietal+Th. | N/A |
| 10 | 6 | French Bulldog | M | 3 | 4 | N/A | Frontal | Olig. III |
Age in years; CAV vaccination in months.
CAV, canine adenovirus; F, female; GBM, glioblastoma multiforme; M, male; N/A, not available; Occ., Occipital; Olig. III, oligodendroglioma grade III; PD, progressive disease; PR, partial response; RAVNO, response assessment in veterinary neuro-oncology; SD, stable disease; Temp., temporal; Th., thalamus.